BioTuesdays

Category - Markets

Neuronetics Logo

BTIG ups Neuronetics PT to $10 from $6

BTIG raised its price target for Neuronetics (NASDAQ:STIM) to $10 from $6, citing takeaways from recent virtual investor meetings, which focused on how the company’s new CEO, Keith Sullivan, will be reshaping the...

WB starts Chinook Therapeutics at OP

William Blair initiated coverage of Chinook Therapeutics (NASDAQ:KDNY) with an “outperform” rating. The stock closed at $14.60 on Oct. 5. Chinook recently completed a merger with Aduro Biotech to become a leading...

SVB Leerink starts Immunic at OP, PT $45

SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...

Evofem Biosciences Logo

Stifel starts Evofem Biosciences at buy; PT $5

Stifel initiated coverage of Evofem Biosciences (NASDAQ:EVFM) with a “buy” rating and price target of $5. The stock closed at $2.36 on Oct. 1. The company recently launched a vaginal pH-modulator gel, Phexxi, offering a...

Catabasis Pharma

HCW starts Catabasis Pharma at buy; PT $24

H.C. Wainwright launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $24 price target. The stock closed at $6.19 on Sept. 30. Catabasis is developing edasalonexent, an oral small molecule...

Selecta Biosciences

William Blair cuts Selecta Biosciences to MP

William Blair downgraded Selecta Biosciences (NASDAQ:SELB) to “market perform” after the company and partner, Swedish Orphan Biovitrum, announced top-line data from the Phase 2 COMPARE trial, comparing Selecta’s SEL-212...

AGP starts Trulieve Cannabis at buy; PT $40 (Canadian)

Alliance Global Partners launched coverage of Trulieve Cannabis (CSE:TRUL) with a “buy” rating and $40 (Canadian) price target. The stock was quoted at $23.74 in afternoon trading on Sept. 25. “We view Trulieve as a...

AGP starts Columbia Care at buy; PT $8 (Canadian)

Alliance Global Partners initiated coverage of Columbia Care (CSE:CCHW) with a “buy” rating and price target of $8 (Canadian). The stock was quoted at $4.41 in afternoon trading on Sept. 25. Columbia Care engages in...

Maxim starts Monopar Therapeutics at buy; PT $11

Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...